Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Therapy

Avoiding treatment failures associated with HCV resistance

Nature Reviews Gastroenterology & Hepatology volume 12, pages 673–674 (2015)Cite this article

Subjects

Treatment failure associated with HCV resistance to newly developed direct-acting antiviral agents is not an uncommon occurrence and poses a substantial problem to clinicians trying to re-treat patients who have failed available interferon-free treatments. A new study suggests that host-targeted agents are the way forward, but is this approach really feasible?

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Pawlotsky, J. M. New hepatitis C therapies: the toolbox, strategies, and challenges. Gastroenterology 146, 1176–1192 (2014).

    Google Scholar 

  2. Pawlotsky, J. M. Hepatitis C treatment: the data flood goes on. An update from The Liver Meeting 2014. Gastroenterology 148, 468–479 (2015).

    Google Scholar 

  3. European Association for Study of the Liver. EASL Recommendations on treatment of hepatitis C 2015. J. Hepatol. 63, 199–236 (2015).

  4. AASLD-IDSA HCV Guidance Panel. Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus. Hepatology 62, 932–954 (2015).

  5. Zeuzem, S. et al. Grazoprevir-elbasvir combination therapy for treatment-naive cirrhotic and noncirrhotic patients with chronic hepatitis C virus genotype 1, 4, or 6 infection: a randomized trial. Ann. Intern. Med. 163, 1–13 (2015).

    Google Scholar 

  6. Dvory-Sobol, H. et al. Long-term persistence of HCV NS5A variants after treatment with NS5A inhibitor ledipasvir [abstract O059]. J. Hepatol. 62, S221 (2015).

    Google Scholar 

  7. Krishnan, P. et al. Long-term follow-up of treatment-emergent resistance-associated variants in NS3, NS5A and NS5B with paritaprevir/r-, ombitasvir- and dasabuvir-based regimens [abstract O057]. J. Hepatol. 62, S220 (2015).

    Google Scholar 

  8. Vercauteren, K. et al. Targeting a host-cell entry factor barricades antiviral-resistant HCV variants from on-therapy breakthrough in human-liver mice. Gut http://dx.doi.org/10.1136/gutjn-2014-309045

  9. Flisiak, R. et al. The cyclophilin inhibitor Debio-025 shows potent anti-hepatitis C effect in patients coinfected with hepatitis C and human immunodeficiency virus. Hepatology 47, 817–826 (2008).

    Google Scholar 

  10. Pawlotsky, J. M. et al. Alisporivir plus ribavirin, interferon free or in combination with pegylated interferon, for hepatitis C virus genotype 2 or 3 infection. Hepatology 62, 1013–1023 (2015).

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Virology, National Reference Center for Viral Hepatitis B, C and D, and INSERM U955, Hôpital Henri Mondor, Université Paris-Est, 51 Avenue du Maréchal de Lattre de Tassigny, Créteil, 94010, France

    Jean-Michel Pawlotsky

Authors
  1. Jean-Michel Pawlotsky
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jean-Michel Pawlotsky.

Ethics declarations

Competing interests

J.M.P. has received research grants from Gilead Sciences and has served as an advisor for Abbvie, Bristol-Myers Squibb, Gilead Sciences, Janssen and Merck.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Pawlotsky, JM. Avoiding treatment failures associated with HCV resistance. Nat Rev Gastroenterol Hepatol 12, 673–674 (2015). https://doi.org/10.1038/nrgastro.2015.184

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrgastro.2015.184

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing